Mangoceuticals Regains Full Compliance With Nasdaq Minimum Bid Price Requirement
Mangoceuticals Regains Full Compliance With Nasdaq Minimum Bid Price Requirement
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that the Company received a letter on October 30, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Requirement").
Mangoceuticals, Inc.（NASDAQ:MGRX）（"MangoRx"或"公司"），是一家专注于通过安全远程医疗平台开发、营销和销售男性健康与福祉产品的公司，今天宣布公司于2024年10月30日收到了纳斯达克股票交易所（"Nasdaq"）发来的一封信件，表明公司已恢复符合纳斯达克依据纳斯达克上市规则5550(a)(2)（"最低买盘价格要求"）继续上市所需的最低买盘价格要求。
As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company's common stock was at or above $1.00 per share. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.
正如信中所示，纳斯达克确定公司普通股连续10个交易日的收盘买盘价格均达到或超过每股$1.00。因此，公司已符合最低买盘价格要求，此事已终结。
